These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9833164

  • 1. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
    Andersson OK.
    Basic Res Cardiol; 1998; 93 Suppl 2():54-8. PubMed ID: 9833164
    [Abstract] [Full Text] [Related]

  • 2. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK, Neldam S.
    Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
    [Abstract] [Full Text] [Related]

  • 3. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 4. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 5. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 6. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT, O'Kane KP, Jonker J, Roth J.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [Abstract] [Full Text] [Related]

  • 8. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec 11; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

  • 9. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Kloner RA, Weinberger M, Pool JL, Chrysant SG, Prasad R, Harris SM, Zyczynski TM, Leidy NK, Michelson EL, Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Am J Cardiol; 2001 Mar 15; 87(6):727-31. PubMed ID: 11249891
    [Abstract] [Full Text] [Related]

  • 10. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000 Mar 15; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr 15; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 12. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 15; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 13. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ, Goa KL.
    Drugs; 1998 Nov 15; 56(5):847-69. PubMed ID: 9829158
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T, Arakawa K.
    J Hum Hypertens; 1999 Jan 15; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF.
    J Hum Hypertens; 2000 Apr 15; 14(4):263-9. PubMed ID: 10805052
    [Abstract] [Full Text] [Related]

  • 16. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE, Jarvis B.
    Drugs; 2002 Apr 15; 62(8):1253-87. PubMed ID: 12010090
    [Abstract] [Full Text] [Related]

  • 17. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
    Oparil S.
    Am J Cardiol; 1999 Nov 18; 84(10A):35S-41S. PubMed ID: 10588093
    [Abstract] [Full Text] [Related]

  • 18. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
    Zuschke CA, Keys I, Munger MA, Carr AA, Marinides GN, Flanagan TL, Cushing DJ, Hayes JL, Michelson EL.
    Clin Ther; 1999 Mar 18; 21(3):464-74. PubMed ID: 10321416
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y, Asmar R.
    Am J Hypertens; 1999 Dec 18; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [Abstract] [Full Text] [Related]

  • 20. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 18; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.